Neil Kumar
CIK: 0001742485
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (196 total)
- Sep 17, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect1.3K shares at avg. $69.57$89K - Sep 17, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect8.7K shares at avg. $69.01$602K - Aug 19, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect1.8K shares at avg. $84.69$152K - Aug 19, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect8.1K shares at avg. $83.86$679K - Aug 19, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect100 shares at avg. $85.65$9K - Aug 18, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Direct1.2K shares at avg. $83.77$100K - Aug 18, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Direct1.9K shares at avg. $81.15$154K - Aug 18, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Direct17.3K shares at avg. $82.21$1.4M - Aug 18, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Direct14.6K shares at avg. $82.99$1.2M - Aug 16, 2026BBIO
BridgeBio Pharma, Inc.
Exercise(M)Direct11.6K shares- - Aug 16, 2026BBIO
BridgeBio Pharma, Inc.
Exercise(M)Direct6.5K shares- - Aug 16, 2026BBIO
BridgeBio Pharma, Inc.
Tax Payment(F)Direct36.2K shares at avg. $79.86$2.9M - Aug 16, 2026BBIO
BridgeBio Pharma, Inc.
Exercise(M)Direct33.5K shares- - Aug 16, 2026BBIO
BridgeBio Pharma, Inc.
Exercise(M)Direct19.6K shares- - Jun 16, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
31.7K shares- - Jun 5, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect7.1K shares at avg. $67.20$480K - Jun 5, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect8.4K shares at avg. $67.88$573K - Jun 5, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect4.4K shares at avg. $68.96$304K - Jun 5, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect4.4K shares at avg. $68.96$305K - Jun 5, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect8.4K shares at avg. $67.88$573K - Jun 5, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect7.1K shares at avg. $67.20$480K - Jun 4, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect1.4K shares at avg. $66.72$95K - Jun 4, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect15.9K shares at avg. $67.74$1.1M - Jun 4, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect450 shares at avg. $68.27$31K - Jun 4, 2026BBIO
BridgeBio Pharma, Inc.
Sale(S)Indirect450 shares at avg. $68.27$31K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 17, 2026 |  BBIO BridgeBio Pharma, Inc. | Sale(S) | 1,279 | $69.57 | $88,980 | Indirect |
| Sep 17, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 8,721 | $69.01 | $601,868 | Indirect |
| Aug 19, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 1,800 | $84.69 | $152,436 | Indirect |
| Aug 19, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 8,100 | $83.86 | $679,256 | Indirect |
| Aug 19, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 100 | $85.65 | $8,565 | Indirect |
| Aug 18, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 1,199 | $83.77 | $100,444 | Direct |
| Aug 18, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 1,900 | $81.15 | $154,184 | Direct |
| Aug 18, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 17,279 | $82.21 | $1,420,514 | Direct |
| Aug 18, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 14,602 | $82.99 | $1,211,852 | Direct |
| Aug 16, 2026 | BBIO BridgeBio Pharma, Inc. | Exercise(M) | 11,554 | - | $0 | Direct |
| Aug 16, 2026 | BBIO BridgeBio Pharma, Inc. | Exercise(M) | 6,520 | - | $0 | Direct |
| Aug 16, 2026 | BBIO BridgeBio Pharma, Inc. | Tax Payment(F) | 36,237 | $79.86 | $2,893,887 | Direct |
| Aug 16, 2026 | BBIO BridgeBio Pharma, Inc. | Exercise(M) | 33,544 | - | $0 | Direct |
| Aug 16, 2026 | BBIO BridgeBio Pharma, Inc. | Exercise(M) | 19,599 | - | $0 | Direct |
| Jun 16, 2026 |  BBOT BridgeBio Oncology Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 31,675 | - | - | Direct |
| Jun 5, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 7,148 | $67.20 | $480,338 | Indirect |
| Jun 5, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 8,437 | $67.88 | $572,744 | Indirect |
| Jun 5, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 4,415 | $68.96 | $304,455 | Indirect |
| Jun 5, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 4,416 | $68.96 | $304,524 | Indirect |
| Jun 5, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 8,437 | $67.88 | $572,744 | Indirect |
| Jun 5, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 7,147 | $67.20 | $480,271 | Indirect |
| Jun 4, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 1,429 | $66.72 | $95,347 | Indirect |
| Jun 4, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 15,921 | $67.74 | $1,078,452 | Indirect |
| Jun 4, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 450 | $68.27 | $30,721 | Indirect |
| Jun 4, 2026 | BBIO BridgeBio Pharma, Inc. | Sale(S) | 450 | $68.27 | $30,721 | Indirect |
1-25 of 196 transactions
About Kumar Neil
Kumar Neil (SEC CIK 0001742485) files insider reports with the SEC as Chief Executive Officer of BridgeBio Pharma, Inc. (BBIO) and Director of BridgeBio Oncology Therapeutics, Inc. (BBOT).
Signal8 holds 38 ownership filings by Kumar Neil (1 Form 3, 37 Form 4), filed between Nov 19, 2024 and Sep 21, 2026. Those filings report 196 transactions, from Nov 16, 2024 to Sep 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kumar Neil's filings is in PALO ALTO, CA.
Recent filings by Kumar Neil
- Sep 17, 2026: Open-market sales of BBIO shares (2 lines, Form 4, code S).
- Aug 19, 2026: Open-market sales of BBIO shares (3 lines, Form 4, code S).
- Aug 18, 2026: Open-market sales of BBIO shares (4 lines, Form 4, code S).
- Aug 16, 2026: Option exercises of BBIO shares (2 lines, Form 4, code M).
- Aug 16, 2026: Tax withholding of BBIO shares (Form 4, code F).
Other insiders filing for BridgeBio Pharma, Inc. (BBIO)
- Apuli Maricel, Chief Accounting Officer
- Trimarchi Thomas, President and CFO
- Ellis Andrea, Director
- Cook Jennifer E., Director
- Valantine Hannah, Director
- Lo Andrew, Director